Yixuan Deng, Yani Feng, Bangming Ye, Lei Hu, Lixin Qi, Chenyi Wang, Chunting Zhou, Guanhao Liu, Xiuying Gao, Congying Lin, Qiang Ding, Ziming Zhao, Chunyu Song, Bo Qian, Tianhao Wu, Xingyun Wang, Zhiming Liu, Zhenlang Lin, Min Zhang
{"title":"纳米材料在中枢神经系统疾病中的应用。","authors":"Yixuan Deng, Yani Feng, Bangming Ye, Lei Hu, Lixin Qi, Chenyi Wang, Chunting Zhou, Guanhao Liu, Xiuying Gao, Congying Lin, Qiang Ding, Ziming Zhao, Chunyu Song, Bo Qian, Tianhao Wu, Xingyun Wang, Zhiming Liu, Zhenlang Lin, Min Zhang","doi":"10.1007/s00213-025-06862-3","DOIUrl":null,"url":null,"abstract":"<p><p>There is a common mechanism in the pathogenesis of central nervous system diseases: Neuronal damage causes a dissipation of the intermediate metabolites, triggering a wider range of injury and inflammation. Due to the selective permeability of the blood-brain barrier, the drug treatment of neurological diseases is not effective. Nanomedicine, with good biocompatibility and high plasticity, can pass through the blood-brain barrier through various mechanisms and targeted the lesion: The nano-delivery system helps drugs cross the blood-brain barrier while taking advantage of its high drug-loading capacity to achieve combined treatment; Nano-enzymes can simulate the enzymatic reaction in biological body to remove metabolic substances, and are more stable and economical than biological enzymes; Individual nanomedicine can regulate the differentiation process of neural stem cells from the genetic level, increase the number of neurons, and repair injured nerves. Nanomaterials can not only improve the pharmacokinetics and pharmacodynamics, but also play the function of focal location to monitor and evaluate the disease and condition during the treatment of nervous system diseases. In this paper, the mechanism of nanomaterials penetrating the blood-brain barrier (BBB) and locating lesions in various nervous system diseases is reviewed, which opens up new ideas for further exploring the application of nanotechnology in central nervous system diseases.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Application of nanomaterials in central nervous system disorders.\",\"authors\":\"Yixuan Deng, Yani Feng, Bangming Ye, Lei Hu, Lixin Qi, Chenyi Wang, Chunting Zhou, Guanhao Liu, Xiuying Gao, Congying Lin, Qiang Ding, Ziming Zhao, Chunyu Song, Bo Qian, Tianhao Wu, Xingyun Wang, Zhiming Liu, Zhenlang Lin, Min Zhang\",\"doi\":\"10.1007/s00213-025-06862-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>There is a common mechanism in the pathogenesis of central nervous system diseases: Neuronal damage causes a dissipation of the intermediate metabolites, triggering a wider range of injury and inflammation. Due to the selective permeability of the blood-brain barrier, the drug treatment of neurological diseases is not effective. Nanomedicine, with good biocompatibility and high plasticity, can pass through the blood-brain barrier through various mechanisms and targeted the lesion: The nano-delivery system helps drugs cross the blood-brain barrier while taking advantage of its high drug-loading capacity to achieve combined treatment; Nano-enzymes can simulate the enzymatic reaction in biological body to remove metabolic substances, and are more stable and economical than biological enzymes; Individual nanomedicine can regulate the differentiation process of neural stem cells from the genetic level, increase the number of neurons, and repair injured nerves. Nanomaterials can not only improve the pharmacokinetics and pharmacodynamics, but also play the function of focal location to monitor and evaluate the disease and condition during the treatment of nervous system diseases. In this paper, the mechanism of nanomaterials penetrating the blood-brain barrier (BBB) and locating lesions in various nervous system diseases is reviewed, which opens up new ideas for further exploring the application of nanotechnology in central nervous system diseases.</p>\",\"PeriodicalId\":20783,\"journal\":{\"name\":\"Psychopharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00213-025-06862-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06862-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Application of nanomaterials in central nervous system disorders.
There is a common mechanism in the pathogenesis of central nervous system diseases: Neuronal damage causes a dissipation of the intermediate metabolites, triggering a wider range of injury and inflammation. Due to the selective permeability of the blood-brain barrier, the drug treatment of neurological diseases is not effective. Nanomedicine, with good biocompatibility and high plasticity, can pass through the blood-brain barrier through various mechanisms and targeted the lesion: The nano-delivery system helps drugs cross the blood-brain barrier while taking advantage of its high drug-loading capacity to achieve combined treatment; Nano-enzymes can simulate the enzymatic reaction in biological body to remove metabolic substances, and are more stable and economical than biological enzymes; Individual nanomedicine can regulate the differentiation process of neural stem cells from the genetic level, increase the number of neurons, and repair injured nerves. Nanomaterials can not only improve the pharmacokinetics and pharmacodynamics, but also play the function of focal location to monitor and evaluate the disease and condition during the treatment of nervous system diseases. In this paper, the mechanism of nanomaterials penetrating the blood-brain barrier (BBB) and locating lesions in various nervous system diseases is reviewed, which opens up new ideas for further exploring the application of nanotechnology in central nervous system diseases.
期刊介绍：
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
